Compounds > ter 286
Page last updated: 2024-09-04

ter 286 and Benign Neoplasms

ter 286 has been researched along with Benign Neoplasms in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's5 (71.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boulos, L; Brown, GL; Brown, J; Dombroski, JA; Gomez, RF; Henner, WD; Keck, JG; Laxa, B; Lum, RT; Maack, CA; Mascavage, JC; Reiswig, L; Rosen, LS; Schow, SR1
Boulos, L; Brown, GL; Jameson, AJ; Keck, JG; Laxa, B; Parra, R; Patel, K; Rosen, LS; Wiggins, L1
Cathcart, C; Lee, FC; Norenberg, JP; Smith, HO; Verschraegen, CF1
Findlay, VL; Tew, KD; Townsend, DM1
Borch, RF; Broberg, U; Henner, WD; Izbicka, E; Kauvar, LM; Mangold, G; Mannervik, B; Morgan, AS; Niitsu, Y; Paul, C; Sanderson, PE; Takayama, T; Tew, KD; Von Hoff, DD1
Henner, WD; Kauvar, LM; Morgan, AS; Sanderson, PE1

Reviews

4 review(s) available for ter 286 and Benign Neoplasms

ArticleYear
TLK 286.
    Drugs in R&D, 2004, Volume: 5, Issue:2

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Glutathione; Humans; Mice; Neoplasms

2004
TLK-286.
    IDrugs : the investigational drugs journal, 2004, Volume: 7, Issue:8

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drugs, Investigational; Glutathione; Humans; Neoplasms

2004
Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
    Methods in enzymology, 2005, Volume: 401

    Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Agents; Azo Compounds; Cisplatin; Cytotoxins; Drug Combinations; Glutathione; Glutathione Disulfide; Glutathione Transferase; Humans; Molecular Structure; Neoplasms; Oxidative Stress; para-Aminobenzoates; Prodrugs; Protein Kinases; Signal Transduction

2005
Glutathione based approaches to improving cancer treatment.
    Chemico-biological interactions, 1998, Apr-24, Volume: 111-112

    Topics: Animals; Antineoplastic Agents; Biotransformation; Cytotoxins; Drug Resistance; Enzyme Inhibitors; Female; Glutathione; Glutathione Transferase; Hematopoiesis; Humans; Male; Neoplasms

1998

Trials

2 trial(s) available for ter 286 and Benign Neoplasms

ArticleYear
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

    Topics: Adult; Aged; Cytotoxins; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms

2003
Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-01, Volume: 10, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytotoxins; Female; Follow-Up Studies; Glutathione; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasm Metastasis; Neoplasms; Time Factors

2004

Other Studies

1 other study(ies) available for ter 286 and Benign Neoplasms

ArticleYear
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
    Cancer research, 1998, Jun-15, Volume: 58, Issue:12

    Topics: Animals; Antineoplastic Agents, Alkylating; Cytotoxins; Glutathione; Glutathione Transferase; Humans; Mice; Mice, Nude; Neoplasms; Prodrugs; Subrenal Capsule Assay; Survival Analysis; Tumor Cells, Cultured; Tumor Stem Cell Assay

1998